Myo-Inositol in PCOS: Dosing, Forms and Why Sachets Matter

Myo-inositol is an insulin-sensitising agent used in PCOS management. It is not a hormone and not a contraceptive — it works upstream, on the insulin resistance that drives much of the anovulation, and it is typically taken for months rather than weeks. Halefem carries it as CYSTOFEM sachets, available for gynae PCD franchise across India.

What myo-inositol actually does

Polycystic ovary syndrome is, for a large proportion of patients, a metabolic problem expressing itself as a reproductive one. Insulin resistance raises circulating insulin, higher insulin drives ovarian androgen production, and the androgen excess disrupts follicular development. That is the loop a gynaecologist is trying to interrupt.

Myo-inositol is a second messenger in the insulin signalling pathway. Supplementing it improves insulin sensitivity, and in doing so tends to lower androgen levels and support the return of ovulatory cycles. It is why the molecule sits alongside letrozole and clomiphene in a fertility clinic’s PCOS protocol rather than competing with them — the induction agents force an ovulation, myo-inositol works on the reason ovulation stopped.

Indian practice commonly pairs it with D-chiro-inositol in a 40:1 ratio, which reflects the physiological ratio in most tissues, and often with folic acid.

Why the sachet matters

This is the part distributors underestimate, and it is the difference between a product that reorders and one that sits.

The usual therapeutic dose of myo-inositol is measured in grams, not milligrams — commonly around 2 g twice daily. That quantity does not fit into a tablet a patient will willingly swallow. Delivering it as a tablet means either several tablets per dose or a compromised dose, and both routes end the same way: the patient stops.

A sachet dissolved in water delivers the full gram-level dose in one go, is easier to tolerate, and sidesteps the pill burden entirely — which matters when the same patient may also be on metformin, a prenatal supplement and an induction agent in the same cycle.

Sachets are also sealed as single doses, which protects a hygroscopic powder that would otherwise clump in an Indian summer.

Why this molecule is good business for a distributor

Three properties make myo-inositol unusually attractive in a gynae PCD portfolio.

It is chronic. Courses run for months, not a week. A PCOS patient started on inositol in March is still on it in July. Compare that to an antibiotic course, where one prescription is the entire relationship.

It is specialist-led. The prescribing concentrates in fertility clinics and gynaecologists running PCOS caseloads. That means a small number of doctors in your district generate a disproportionate share of the volume — win three of them and the numbers work.

It is sticky. Neither the doctor nor the patient wants to switch brand mid-protocol once a cycle is running and responding. Consistency of supply is what protects that stickiness, which is also the fastest way to lose it: a distributor who is out of stock in month three hands the prescription to a competitor permanently.

CYSTOFEM — the Halefem brand

CYSTOFEM is Halefem Gynae’s myo-inositol sachet, part of the female infertility and PCOS-PCOD management series. It sits alongside letrozole (HALTRO), clomiphene citrate (CLOMIHAL and CLOMIHAL U 100), DHEA (OVADONE) and human chorionic gonadotrophin injection — so a partner can supply the whole PCOS and induction protocol rather than one piece of it.

Products are manufactured at WHO-GMP compliant units at Sai Road, Baddi, Himachal Pradesh, with packing matched to the molecule. Full composition, strength and pack details are on the current product list, revised every April and issued on request.

What to expect when you detail it

A gynaecologist will ask you three things about an inositol sachet, and you should be able to answer all three without reaching for a folder:

• What ratio? Whether it is myo-inositol alone or combined with D-chiro-inositol, and in what ratio.
• What else is in it? Folic acid content, and whether anything else is added.
• How does it taste? Not a trivial question. A sachet a patient dislikes is a sachet she stops taking in week two, and the doctor hears about it before you do.

Frequently asked questions

What is myo-inositol used for in PCOS?

It is used to improve insulin sensitivity in polycystic ovary syndrome. By acting on insulin signalling it tends to reduce androgen excess and support the return of ovulatory cycles, which is why it is prescribed alongside ovulation induction agents rather than instead of them.

Why is myo-inositol supplied as a sachet rather than a tablet?

Because the therapeutic dose is measured in grams. A dose of roughly 2 g twice daily will not fit into a tablet a patient will reliably take, so a sachet dissolved in water delivers the full dose in one go and protects compliance.

What is the 40:1 myo-inositol to D-chiro-inositol ratio?

It reflects the ratio in which the two forms occur in most human tissues, and it is the combination most commonly used in Indian PCOS practice.

Is myo-inositol available for PCD franchise in India?

Yes. Halefem Gynae supplies myo-inositol sachets as CYSTOFEM to franchise partners across India, with monopoly rights district by district. A valid drug licence and GST registration in your own name are required.

Available for gynae PCD franchise across India

Halefem Gynae markets 200+ gynae formulations across six therapeutic series, one partner per district. Tell us your district and we will tell you within a working day whether it is open.

Call +91-9888020547, see the full gynae product range, read about the gynae PCD pharma franchise, or find out what we provide as franchise partner support. Price list on request.

Halefem Gynae — a gynae division of Edmund Healthcare Pvt. Ltd., an ISO 9001:2015 certified company. Products manufactured at WHO-GMP compliant units, Sai Road, Baddi, Himachal Pradesh.

This article is written for pharmaceutical distributors and healthcare professionals in India. It is not medical advice and not a recommendation to any patient. Prescribing decisions rest with the treating clinician.